Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Tech rout led to another session of weakness on Wall Street on Tuesday as heavily-weighted Nvidia (NVA), peer AMD (AMD), and ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Per management, Keytruda will remain a key revenue driver for the company in the second half of 2025, along with the Animal ...

Merck has partnered with company builder mantro GmbH to launch EdiMembre, a deep-tech spinout that will commercialize Merck's ...

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies based on ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma Inc in 2021, underscoring the company’s commitment to advancing innovative therapies for serious medical conditions.

Shares of Merck & Co. took a dive Tuesday, after the drugmaker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, but provided a ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.